Representative matters
- Centocor (Johnson & Johnson) v Bayer, concerning the anti-TNF-alpha drug golimumab.
- Abbott v Medinol, concerning coronary stents.
- Medimmune v Novartis, concerning the basic patents on phage display.
- AGA v Occlutech, concerning cardiac implants (ASD/PFO occluders).
- RCT v Accord, concerning lacosamide.
- Warner Lambert v Dutch State, concerning pregabalin and regulatory law (ECJ referral).
- Royalty Pharma v MSD, concerning DPP-4 inhibitors.
- AbbVie v Biosimilars, concerning the defense of AbbVie’s portfolio of patents on adalimumab (Humira).
- Abbott v Edwards, concerning heart implants.
- Regeneron v Amgen, concerning PCSK9 inhibitors.
- Wyeth v MSD, concerning multivalent pneumococcal vaccines.
- CEVA v Bayer, concerning a veterinary combination drug against anaemia and coccidiosis.
- Apple v Ericsson, on 4G/5G telecom technology
- BioNtech / Moderna, on MRNA vaccines
- Janssen / Samsung, on an IL12/IL23 antibody for the treatment of ulcerative colitis
- Regeneron / Samsung, concerning VEGF-antagonists for wAMD
- Gilead / AMMS (UPC), concerning SARS-CoV-2 therapies
- Washtower / BEGA (UPC), concerning a mechanical invention and the doctrine of equivalence.
